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Abstract 
To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 
most important questions in cancer research and clinical oncology. In this article, nine more questions are presented 
as followed. Question 6. Why do nasopharyngeal carcinomas rarely metastasize to the brain? Question 7. Can distant 
spread of cancer cells be blocked by inhibiting the remodeling of high endothelial venules in the sentinel lymph 
node? Question 8. What sort of live-imaging techniques can be developed to directly observe the dynamic processes 
of metastasis? Question 9. How does chronic hepatitis prevent liver metastasis from colorectal cancer? Question 10. 
How many types of host cells contribute to forming the pre-metastatic niche in the lung favorable for metastasis? 
Question 11. Why do cancers rarely metastasize to the small bowel? Question 12. Why do glioblastomas rarely metas-
tasize outside the central nervous system? Question 13. Despite increased understanding of the molecular genetic 
events leading to the development and progression of high-grade gliomas, these tumors are the most therapeutically 
refractory among all human cancers. What then would be the most effective therapeutic approaches to treat what in 
essence can be regarded as a whole brain malignancy, since even a surgical resection of greater than 99% of tumor 
tissues is invariably associated with recurrence? Question 14. The blood–brain barrier (BBB) effectively limits a wide 
variety of potential therapeutic agents from reaching glioma cells widely dispersed in the brain. What therapeutic 
approaches can be used to breach the BBB and allow therapeutic agents to seek out and kill these tumor cells?
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To accelerate our endeavors to overcome cancer, Chi-
nese Journal of Cancer has launched a program of pub-
lishing 150 most important questions in cancer research 
and clinical oncology [1], with the first five questions 
been published in the last two issues [2, 3]. In this article, 
questions 6–14 are selected and presented. Chinese Jour-
nal of Cancer is still open to collect more key questions 
in cancer research and clinical oncology. Please send 
us your thoughtful questions to Ms. Ji Ruan via email: 
ruanji@sysucc.org.cn.
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Question 6: Why do nasopharyngeal carcinomas 
rarely metastasize to the brain?
Background and implications
Of all head and neck cancers, nasopharyngeal carcinoma 
(NPC) has the highest metastasis rate. NPCs commonly 
metastasize to the lymph nodes, bone, liver, and lung. 
Given the close anatomic location of the nasopharynx to 
the brain, NPCs rarely metastasize to the brain. Deter-
mining the underlying molecular mechanism(s) may be 
very helpful for preventing brain metastases from other 
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Question 7: Can distant spread of cancer cells 
be blocked by inhibiting the remodeling of high 
endothelial venules in the sentinel lymph node?
Background and implications
The sentinel lymph node is the most common first station 
in the metastatic cascade of carcinomas. The occurrence 
rate of distant metastasis is much higher in the patients 
with sentinel lymph node involvement than in those 
without sentinel lymph node metastasis. Therefore, the 
prognosis of cancer patients with sentinel lymph node 
involvement is usually poorer than that of the patients 
without sentinel lymph node involvement.
Our previous investigation has confirmed that primary 
tumor can induce vascular remodeling of high endothe-
lial venules (HEVs) in the sentinel lymph node even 
before the arrival of metastatic cancer cells. The normal 
physiological function of HEVs is to provide an extrava-
sation site for circulating naïve lymphocytes into the 
lymphoid tissue. Therefore, there are few or no red blood 
cells inside normal HEVs. The HEV remodeling induced 
by primary tumor is characterized by (1) enlargement 
of HEV lumen space; (2) reduced vessel wall thickness; 
(3) increased proliferation rate in the endothelial cells 
of HEV; and (4) increased red blood cell number inside 
the HEV lumen space. After cancer cell arrival, the meta-
static cancer nests can unlimitedly expand and eventu-
ally occupy the whole lymph node, while the remodeled 
HEVs become the mother vessels of the metastatic 
tumor accompanied by further remodeling of HEVs 
characterized by the loss of their normal immunological 
function for lymphocyte extravasation.
It is critical to clarify whether HEV remodeling in 
the sentinel lymph node could facilitate further spread 
of cancer cells from the sentinel lymph node to distant 
organs. If our speculation of the role of HEV remodeling 
in cancer metastasis is true, we could then block further 
spread of cancer cells from the sentinel lymph node by 
inhibiting the remodeling procedure of HEV. Answer-
ing this question would open a new door for us to block 
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Question 8: What sort of live‑imaging techniques 
can be developed to directly observe the dynamic 
processes of metastasis?
Background and implications
There is extensive work on investigating cancer metas-
tasis in animal models, particularly end-point data on 
established metastasis, with standard textbook mod-
els commonly describing classical sequential models 
of cancer metastasis (“late metastasis”). In recent years, 
these models are challenged by early metastasis models, 
as more data accrue on clonality of distant metastasis. 
While live-imaging animal models allow monitoring of 
these processes in animals, there is little direct data and 
observations on the dynamic processes of cancer metas-
tasis in humans, such as tumor cell intravasation, trans-
port through circulation, and extravasation at distant 
site. It would be important to establish live-imaging tech-
niques using innovative bioengineering approaches that 
would allow for sensitive detection and measurement of 
these processes. Such observations will certainly shed 
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Question 9: How does chronic hepatitis prevent 
liver metastasis from colorectal cancer?
Background and implications
Liver metastasis has been commonly seen in over 50% of 
patients with colorectal cancer. Chronic hepatitis caused 
by hepatitis B and C virus infection has been recognized 
as precancerous alteration for hepatocellular carcinoma. 
Interestingly, in colorectal cancer patient with chronic 
hepatitis, liver metastasis is rare. Obviously, chronic hep-
atitis prevents the manifestation of liver metastasis from 
colorectal cancer. Determining the underlying molecular 
mechanism(s) may be very helpful for preventing liver 
metastases from other types of malignancy that are prone 
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Question 10: How many types of host cells 
contribute to forming the pre‑metastatic niche 
in the lung favorable for metastasis?
Background and implications
It is estimated that approximately 70% of cancer patients 
are died of tumor metastasis; among the patients who are 
succumbed to tumor metastasis, 20%–30% suffer from 
pulmonary metastasis. Numerous studies have dem-
onstrated that forming the pre-metastatic niche in the 
lung is a critical step in the progression of pulmonary 
metastasis. Several types of primary tumor displayed 
the potential ability to “prepare” a supportive and recep-
tive microenvironment in the lung for licensing circulat-
ing tumor cells (CTCs) colonization even before their 
arrival. Interestingly, compelling evidence showed that 
the formation of pre-metastatic niche was greatly associ-
ated with the interaction between tumor cells and host 
cells. In the stress of tumor-derived secreted factors and 
extracellular vesicles derived from the primary micro-
environment, the local lung stroma can be reformed to 
be a favorable secondary microenvironment for settle-
ment and progression of CTCs. The known cell types 
recruited to this altered microenvironment for metastasis 
include VEGFR1+  VLA-4+  bone marrow-derived cells, 
myeloid-derived suppressor cells, myeloid cells (Mac1+, 
CD11b+ CD68+ F4/80+, CD11b+/Mac1+, CD11b+/Gr-1+, 
CD11b+/Ly6Cmed/Ly6G+), monocytes (CD11b+  Ly6C+, 
IE2+, CD11b+/Gr1+), CD11b+  Ly6G+  Ly6C+  granu-
locytes, tumor-associated macrophages, regulatory T 
cells, VEGFR1+  VLA-4+  hematopoietic progenitor cells, 
endothelial progenitor cells, and neutrophils.
It is speculated that multiple cell types from the host 
are recruited to the pre-metastatic niche through a well-
organized procedure coordinated by the primary tumor. 
Before unveiling the crosstalk among different host cell 
types, an essential question would be as follows: have 
we identified all cell types in the pre-metastatic niche? 
Answering this question would be very useful for better 
understanding the formation of pre-metastatic niche in 
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Question 11: Why do cancers rarely metastasize 
to the small bowel?
Background and implications
Of all the organs that may have cancer metastasis, the 
small bowel has the lowest metastasis rate. Determining 
the underlying molecular mechanism(s) through which 
the small bowel keeps away from metastasis may be very 
helpful for preventing metastases from different malig-
nancies that are prone to spread to specific organs.
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Question 12: Why do glioblastomas rarely 
metastasize outside the central nervous system?
Background and implication
Contrasting to extracranial cancers, glioblastomas are 
primarily formed in the brain and rarely metastasize out-
side the central nervous system even after neurosurgery 
which can destroy the blood–brain barrier. Actually, in 
rare circumstances, glioblastoma cells can spread to the 
lung, liver, bone, lymph node, and other distance organs. 
In animal experiments, glioblastoma cells can grow sub-
cutaneously in immuno-deficient mice. All these facts 
suggest that the brain microenvironment is not an indis-
pensable factor for the growth of glioblastoma cells. 
Other key limiting factors should exist to prevent the 
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spreading or survival of glioblastoma cells outside the 
central nervous system. Determining these factors may 
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Question 13: Despite increased understanding 
of the molecular genetic events leading to the 
development and progression of high‑grade 
gliomas, these tumors are the most therapeutically 
refractory among all human cancers. What 
then would be the most effective therapeutic 
approaches to treat what in essence can be 
regarded as a whole brain malignancy, since even 
a surgical resection of greater than 99% of tumor 
tissues is invariably associated with recurrence?
Background and implications
The greatest single advance in the treatment of high-
grade gliomas, and more specifically, glioblastomas 
(GBM), over the past 30  years has been the addition of 
temozolomide (TMZ) to the postoperative radiother-
apy. This has resulted in only a 2.5-month increase in 
the median overall survival, to 14.5 months for patients 
receiving combination therapy, compared with 
12.1  months for those receiving radiotherapy alone. 
Clearly, new therapeutic approaches are needed to treat 
patients with GBMs.
What might these new therapeutic approaches consist 
of? First, it probably will entail a combination of new tar-
geted chemotherapeutic agents that will attack molecu-
lar checkpoints that drive GBMs to proliferate. Second, 
it might include immunotherapeutic approaches directed 
against molecular targets such as programmed death-1 
(PD-1) and tumor-specific antigens expressed on GBM 
cells. Third, it might include the use of oncolytic viruses 
such as genetically engineered herpes and adenoviruses 
that will be able to selectively target infiltrating tumor 
cells interspersed in so-called “normal” brain. Progress is 
being made with each of these approaches, but the chal-
lenge will be to effectively combine them with the current 
standard treatment to eradicate residual tumor cells that, 
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Question 14: The blood–brain barrier (BBB) 
effectively limits a wide variety of potential 
therapeutic agents from reaching glioma cells 
widely dispersed in the brain. What therapeutic 
approaches can be used to breach the BBB 
and allow therapeutic agents to seek out and kill 
these tumor cells?
Background and implications
Curative treatment of glioblastomas requires effective 
delivery of a variety of therapeutic agents to glioma cells 
infiltrating the normal brain tissue. The BBB constitutes 
a significant barrier for the delivery of therapeutic agents 
with molecular weights greater than 200, making drug 
delivery to the brain more complex than to any other 
organ.
At the present time, a variety of approaches have been 
used to allow high molecular weight agents to traverse 
the BBB. These have included BBB disruption by ultra-
sound and hyperosmotic mannitol, the use of trans-
porter carriers such as insulin-like growth factor-1 and 
novel brain-penetrating peptides such as ANG4043 
that can be linked to therapeutic agents such as drug 
bioconjugates, and the direct intracerebral administra-
tion of therapeutic agents to the site of infiltrating gli-
oma cells, completely bypassing the BBB. Each of these 
approaches are currently being evaluated, and hopefully 
one or more of them, combined with new therapeutic 
agents as described in the previous question, will be 
able to selectively target residual proliferating tumor 
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